Table 3.

Summary of the clinical and demographic data for study participantsa

Characteristic	Range or N b	%	Medianc
Age (year)	18–90	NE	51
Weight (kg)	39–180	NE	76
CrCL (mL/minutes)	8–406	NE	109
CrCL categoryd			NE
CrCL < 15 mL/minutes	5	0.6
CrCL mL/minutes ≥ 15 and < 30	9	1.1
CrCL mL/minutes ≥ 30 and < 60	70	8.2
CrCL mL/minutes ≥ 60 and < 90	199	23.4
CrCL mL/minutes ≥ 90 and < 150	439	51.5
CrCL mL/minutes ≥ 150 and < 180	103	12.1
CrCL mL/minutes ≥ 180 and < 210	18	2.1
CrCL mL/minutes ≥ 210 and < 250	4	0.5
CrCL mL/minutes ≥ 250	5	0.6
Gender			NE
Male	519	60.7
Female	336	39.3
Health status			NE
Healthy volunteer	231	27.0
Patients	624	73.0
Race			NE
White	739	86.4
Black	32	3.7
Asian	44	5.2
Other	40	4.7

CrCL, creatinine clearance; NE, not evaluated.

^a855 participants (815 with imipenem measurements and 649 with relebactam measurements).

^bRange (minimum–maximum) is shown for continuous covariates and N, number of participants and %, percentage of total for each category for categorical covariates.

^cMedian value is shown for continuous covariates only.

^dThree participants had missing CrCL values and therefore calculated statistics are shown for the remaining 852.